Unity Biotechnology, Inc. (UBX)

Market Closed

8 Jul, 20:00

NASDAQ (NGS)

0. 20

+0.1

+92.77%

3.44M Market Cap

- P/E Ratio

0% Div Yield

3,356,988 Volume

-3.43 Eps

$ 0.1

Previous Close

Day Range

0.2 0.32

Year Range

0.1 3.1

Want to track UBX and more in your Portfolio? 🎯

Get Started For Free

UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study

UNITY Biotechnology stock loses 29% as the mid-stage DME study of the lead candidate, UBX1325, fails to achieve statistical significance for the primary goal.

Zacks | 8 months ago

Unity Biotechnology Unveils Mixed Data From Study For Diabetes-Related Blindness, Stock Falls

Unity Biotechnology, Inc. UBX stock plummeted on Monday after the company released results from its latest study.

Benzinga | 8 months ago

UNITY Biotechnology (UBX) Upgraded to Buy: Here's What You Should Know

UNITY Biotechnology (UBX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks | 1 year ago

All You Need to Know About UNITY Biotechnology (UBX) Rating Upgrade to Buy

UNITY Biotechnology (UBX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks | 1 year ago

Affiliate Program About Terms Privacy Help Contact Us